article thumbnail

ROHKEA® VR Therapy Achieves MDR Class IIa Certification, Marking Major Milestone in Digital Therapeutics for Chronic Pain

Digital Health Global

This certification validates ROHKEAs intended use is to provide an automated intervention based on cognitive behavioral therapy to help patients overcome fear of movement caused by chronic musculoskeletal pain. ROHKEA is originally developed by Finnish pharmaceutical company Orion.

article thumbnail

Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain

Digital Health Global

As showcased in the ‘ VIRPI ‘ study, ODD-403 marks a statistically significant advancement in chronic pain management. About Orion Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. The core therapy areas of our pharmaceutical R&D are oncology and pain.

article thumbnail

Average Multiples and Key Drivers of Digital Therapeutics (DTx) M&A deals in 2023

Lloyd Price

This is due to a number of factors, including: The increasing prevalence of chronic diseases The rising cost of healthcare The increasing demand for patient-centered care As a result, DTx companies are still expected to be attractive targets for M&A deals. The average deal size for DTx M&A deals is increasing.